{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T14:18:04Z","timestamp":1789827484332,"version":"4.0.1"},"reference-count":19,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T00:00:00Z","timestamp":1690502400000},"content-version":"am","delay-in-days":392,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100007543","name":"Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.therap.2021.12.013","type":"journal-article","created":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T10:37:28Z","timestamp":1640255848000},"page":"445-452","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Replacing liquid with solid dosage forms in pediatric practice: Feasibility and economic impact from a hospital-based study"],"prefix":"10.1016","volume":"77","author":[{"given":"Rama","family":"Arab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behrouz","family":"Kassai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roubi","family":"Kilo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Cornu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabete","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan","family":"Dagonneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2021.12.013_bib0100","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1208\/s12249-016-0584-1","article-title":"European Paediatric Formulation Initiative (EuPFI)-Formulating ideas for better medicines for children","volume":"18","author":"Salunke","year":"2017","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.therap.2021.12.013_bib0105","unstructured":"Committee for Medicinal Products for Human Use (CHMP). Reflection paper: formulations of choice for the paediatric population. 2006. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/reflection-paper-formulations-choice-paediatric-population_en.pdf. [Accessed 17 December 2021 (45 pp.)."},{"key":"10.1016\/j.therap.2021.12.013_bib0110","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/j.1365-2125.2005.02410.x","article-title":"Formulation of medicines for children","volume":"59","author":"Nunn","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2021.12.013_bib0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2008.09.015","article-title":"European Paediatric Formulation Initiative (EuPFI). Challenges of developing palatable oral paediatric formulations","volume":"365","author":"Cram","year":"2009","journal-title":"Int J Pharm"},{"key":"10.1016\/j.therap.2021.12.013_bib0120","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.pharma.2018.01.004","article-title":"Factors influencing the acceptability of pediatric galenic formulations","volume":"76","author":"Rehn","year":"2018","journal-title":"Ann Pharm Fr"},{"key":"10.1016\/j.therap.2021.12.013_bib0125","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1111\/j.1651-2227.2003.tb00837.x","article-title":"Lack of appropriate formulations of medicines for children in the community","volume":"92","author":"Schirm","year":"2003","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.therap.2021.12.013_bib0130","unstructured":"World Health Organization. Report of the Informal Expert Meeting on Dosage Forms of Medicines for Children. 2008. https:\/\/www.who.int\/selection_medicines\/committees\/expert\/17\/application\/paediatric\/Dosage_form_reportDEC2008.pdf. [Accessed 17 December 2021 (15 pp.)]."},{"key":"10.1016\/j.therap.2021.12.013_bib0135","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.phrs.2011.01.006","article-title":"Paediatric pharmacology: remember the excipients","volume":"63","author":"Fabiano","year":"2011","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.therap.2021.12.013_bib0140","unstructured":"Committee for Medicinal Products for Human Use (CHMP). Guideline on pharmaceutical development of medicines for paediatric use. 2013. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-pharmaceutical-development-medicines-paediatric-use_en.pdf. [Accessed 17 December 2021 (24 pp.)]."},{"key":"10.1016\/j.therap.2021.12.013_bib0145","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4155\/tde.12.135","article-title":"Conference report: formulating better medicines for children: 4th European Paediatric Formulation Initiative conference","volume":"4","author":"Walsh","year":"2013","journal-title":"Ther Deliv"},{"key":"10.1016\/j.therap.2021.12.013_bib0150","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ijpharm.2016.01.048","article-title":"Oral drug dosage forms administered to hospitalized children: Analysis of 117,665 oral administrations in a French paediatric hospital over a 1-year period","volume":"500","author":"Lajoinie","year":"2016","journal-title":"Int J Pharm"},{"key":"10.1016\/j.therap.2021.12.013_bib0155","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ijpharm.2005.05.006","article-title":"Paediatric formulations--getting to the heart of the problem","volume":"300","author":"Standing","year":"2005","journal-title":"Int J Pharm"},{"key":"10.1016\/j.therap.2021.12.013_bib0160","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/bcp.12268","article-title":"Formulations for children: problems and solutions","volume":"79","author":"Batchelor","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2021.12.013_bib0165","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1136\/archdischild-2012-303303","article-title":"Acceptability of different oral formulations in infants and preschool children","volume":"98","author":"van Riet-Nales","year":"2013","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.therap.2021.12.013_bib0170","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1111\/bcp.12442","article-title":"Solid oral forms availability in children: a cost saving investigation","volume":"78","author":"Lajoinie","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2021.12.013_bib0175","unstructured":"European Medicines Agency. Note for guidance on clinical investigation of medicinal products in the paediatric. 2001. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use_en-1.pdf. [Accessed 17 December 2021 (13 pp.)]."},{"key":"10.1016\/j.therap.2021.12.013_bib0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2010.11.001","article-title":"Oral drug delivery in personalized medicine: unmet needs and novel approaches","volume":"404","author":"Wening","year":"2011","journal-title":"Int J Pharm"},{"key":"10.1016\/j.therap.2021.12.013_bib0185","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0939-6411(01)00228-4","article-title":"Breaking of scored tablets: a review","volume":"53","author":"van Santen","year":"2002","journal-title":"Eur J Pharm Biopharm"},{"issue":"4","key":"10.1016\/j.therap.2021.12.013_bib0190","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1080\/02813430701652036","article-title":"Factors influencing GPs\u2019 choice between drugs in a therapeutic drug group. A qualitative study","volume":"25","author":"Buusman","year":"2007","journal-title":"Scand J Prim Health Care"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595721002651?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595721002651?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T18:54:15Z","timestamp":1758567255000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595721002651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S0040595721002651"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2021.12.013","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Replacing liquid with solid dosage forms in pediatric practice: Feasibility and economic impact from a hospital-based study","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2021.12.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}